Teleconference Scheduled For June 5, 2007
EMERYVILLE, Calif., May 25 /PRNewswire-FirstCall/ -- Onyx
Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced today that it will
webcast a post-ASCO teleconference on Tuesday, June 5, 2007, beginning at
8:00 a.m. Central Time. Clinical investigators and management will
participate in the event.
The physicians will review recently reported liver cancer data for
Nexavar(R) (sorafenib) tablets, being developed in collaboration with Bayer
Pharmaceuticals Corporation. Interested parties may access a live webcast
of the presentation by clicking on the link below:
http://events.streamlogics.net/conferenceplus/onyx/event001/index.asp
or by dialing 847-413-3362 and using the passcode 17973020. The
accompanying slides will be posted on the Onyx website at
http://www.onyx-pharm.com/wt/page/event_calendar approximately 15 minutes
before the teleconference is scheduled to begin. A replay of the
presentation will be available on the Onyx website through July 5, 2007.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company developing
innovative therapies that target the molecular mechanisms that cause
cancer. The company is developing Nexavar(R), a small molecule drug, with
Bayer Pharmaceuticals Corporation. Nexavar is approved for the treatment of
advanced kidney cancer in approximately 50 countries. For more information
about Onyx's pipeline and activities, visit the company's web site at:
http://www.onyx-pharm.com.
Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer
Pharmaceuticals Corporation.
SOURCE Onyx Pharmaceuticals, Inc.
 back to top
Related links:
http://www.onyx-pharm.com
CONTACT:
Alex Santos of Onyx Pharmaceuticals, Inc.,
+1-510-597-6504
|
